The discovery of these three key biomarkers: nucleolar and spindle-associated protein 1 (NUSAP1), melatonin receptor 1A (MELT), and cyclin-dependent kinase 1 (CDK1), and the potential use of a chimeric peptide in drug delivery represents a significant step forward in our understanding and management of breast cancer. Here, NUSAP1 is linked to breast carcinoma.